These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 12910523

  • 1. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA.
    Cancer; 2003 Aug 15; 98(4):779-88. PubMed ID: 12910523
    [Abstract] [Full Text] [Related]

  • 2. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 3. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L.
    Lung Cancer; 2005 Jan 15; 47(1):111-20. PubMed ID: 15603861
    [Abstract] [Full Text] [Related]

  • 4. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP.
    Cancer; 2008 Aug 01; 113(3):542-6. PubMed ID: 18512224
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M.
    Jpn J Clin Oncol; 2005 Apr 01; 35(4):188-94. PubMed ID: 15845567
    [Abstract] [Full Text] [Related]

  • 6. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH, Paul DM, Hande KR, DeVore R.
    Semin Oncol; 1996 Dec 15; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [Abstract] [Full Text] [Related]

  • 8. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 9. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Jan 20; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP, Leonardo JM, Karlsson U, Vos P, Bullock L, Thomas P, Lepera P, Ludin A, Chu C, Salehpour M, Jendrasiak G, Sallah S.
    Anticancer Res; 2002 Jan 20; 22(6B):3429-35. PubMed ID: 12552935
    [Abstract] [Full Text] [Related]

  • 12. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.
    Lung Cancer; 2007 Nov 20; 58(2):238-45. PubMed ID: 17658655
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
    DeVore RF, Jagasia M, Johnson DH.
    Semin Oncol; 1997 Aug 20; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
    [Abstract] [Full Text] [Related]

  • 14. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
    Tell R, Sederholm C, Klintenberg C, Franksson L, Brandén E, Hillerdal G, Lönn U, Lindén CJ, Ewers SB, Lamberg K, Mrazek E, Lödén B, Sjögren A, Linné T, Friesland S, Sirzén F.
    Anticancer Res; 2008 Aug 20; 28(5B):2851-7. PubMed ID: 19031924
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.
    Gynecol Oncol; 2005 Jan 20; 96(1):168-72. PubMed ID: 15589596
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.
    Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, Gomi K, Koinumaru S, Saijo Y, Nukiwa T.
    Lung Cancer; 2006 Apr 20; 52(1):83-7. PubMed ID: 16483687
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
    Hashizume T, Ogura T, Kozawa S, Yamaguchi N, Hayashi M, Nakamura M, Miyazawa N, Watanuki Y, Takahashi H.
    Gan To Kagaku Ryoho; 2006 Apr 20; 33(4):471-5. PubMed ID: 16612156
    [Abstract] [Full Text] [Related]

  • 19. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A.
    J Clin Oncol; 2008 Apr 10; 26(11):1879-85. PubMed ID: 18398153
    [Abstract] [Full Text] [Related]

  • 20. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
    Hensing TA, Schell MJ, Lee JH, Socinski MA.
    Lung Cancer; 2005 Feb 10; 47(2):253-9. PubMed ID: 15639724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.